Caladrius Biosciences Inc (NASDAQ:CLBS) saw a large drop in short interest in October. As of October 31st, there was short interest totalling 39,800 shares, a drop of 23.6% from the September 30th total of 52,100 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average daily volume of 13,300 shares, the short-interest ratio is currently 3.0 days.
A number of research analysts have weighed in on CLBS shares. ValuEngine upgraded Caladrius Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research lowered Caladrius Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 14th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $8.63.
An institutional investor recently raised its position in Caladrius Biosciences stock. Vanguard Group Inc. lifted its stake in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) by 7.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 207,973 shares of the biotechnology company’s stock after buying an additional 14,740 shares during the quarter. Vanguard Group Inc. owned approximately 2.00% of Caladrius Biosciences worth $474,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.00% of the company’s stock.
Shares of NASDAQ CLBS traded down $0.06 during trading on Friday, hitting $2.71. 40,000 shares of the company were exchanged, compared to its average volume of 15,031. The firm has a market capitalization of $27.77 million, a PE ratio of -1.62 and a beta of 1.46. The company has a fifty day moving average price of $2.32 and a 200-day moving average price of $2.60. Caladrius Biosciences has a 12-month low of $2.00 and a 12-month high of $5.44.
Caladrius Biosciences (NASDAQ:CLBS) last released its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04). On average, analysts anticipate that Caladrius Biosciences will post -1.58 EPS for the current year.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Featured Article: Hang Seng Index (HSI)
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.